Philip L. Johnson serves as the Executive Vice President and Chief Financial Officer (CFO) at Jazz Pharmaceuticals plc, a leading biopharmaceutical company focused on developing and commercializing innovative therapies. With a robust background in finance and strategic leadership within the pharmaceutical industry, Johnson has been instrumental in guiding Jazz Pharmaceuticals through significant growth and development. He joined the company in 2014 and has since played a pivotal role in its financial strategy, including overseeing mergers and acquisitions, capital allocation, and investor relations. Prior to his tenure at Jazz Pharmaceuticals, Johnson held several high-profile positions that honed his expertise in financial management and corporate strategy. He spent over a decade at Amgen, where he served in various roles, including Vice President of Finance and Chief Accounting Officer. During his time at Amgen, he was involved in significant financial planning and analysis, which contributed to the company's strong financial performance. Johnson's strategic acumen and financial leadership have been key factors in his successful career trajectory. At Jazz Pharmaceuticals, Johnson's responsibilities encompass a wide range of financial operations, from budgeting and forecasting to financial reporting and compliance. His strategic vision has helped the company navigate complex market dynamics and capitalize on growth opportunities. Under his leadership, Jazz Pharmaceuticals has strengthened its financial position, enabling continued investment in research and development to bring new treatments to patients worldwide. Johnson's contributions have been vital to the company's success, and his role as CFO continues to be integral to its future growth and innovation.